Stocktoria
Galmed Pharmaceuticals Ltd. GLMD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-03-13
Galmed Pharmaceuticals Ltd. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $4.9M | $3.0M | $3.6M | $13.0M | $27.2M |
| Income tax | $0 | — | — | — | — |
| Net income | -$10.3M | -$7.5M | -$6.9M | -$17.9M | -$32.5M |
| EPS (diluted) | $2.39 | $8.08 | $30.00 | $127.80 | $19.80 |
| Operating cash flow | -$6.3M | -$5.9M | -$6.1M | -$18.5M | -$32.9M |
| Free cash flow | — | — | — | -$18.5M | -$32.9M |
| Cash & equivalents | $4.0M | $4.7M | $2.9M | $2.0M | $2.9M |
| Total assets | $18.6M | $18.5M | $16.6M | $16.6M | $36.6M |
| Shareholders' equity | $15.8M | $16.3M | $13.9M | $13.4M | $30.5M |
Source: SEC EDGAR filings · CIK 0001595353 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.